Genmab A/S (FRA:GE91)

Market Cap	17.99B
Revenue (ttm)	3.28B
Net Income (ttm)	1.35B
Shares Out	n/a
EPS (ttm)	21.39
PE Ratio	13.33
Forward PE	22.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	26.60
Previous Close	27.40
Day's Range	26.60 - 26.60
52-Week Range	15.90 - 28.60
Beta	n/a
RSI	63.18
Earnings Date	Feb 17, 2026

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 2,682
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GE91

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial numbers in USD